Synthesis and Biological Evaluation of Quercetagetin Derivatives as the Inhibitors of Mcl-1 and Bcl-2 Against Leukemia
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26062727 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Kang Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Hunan Key Laboratory of Traditional Chinese Veterinary Medicine, Hunan Agricultural University, Changsha 410128, China. Hauptthemen laut MEDLINE: Myeloid Cell Leukemia Sequence 1 Protein, Proto-Oncogene Proteins c-bcl-2, Leukemia, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China.
Abstract (Originalsprache)
B-cell lymphoma-2 (Bcl-2) family proteins are fundamental regulators of intrinsic cell apoptosis, and overexpression of apoptotic proteins (Bcl-2 and Mcl-1) is a characteristic of many haematological malignancies. Thus, it is necessary to discover novel inhibitors to treat leukemia. In the current study, we synthesized a series of quercetagetin derivatives (compounds 2a–2t, 3a–3j and 4a–4g) and evaluated their anticancer activities on four leukemia cells (U937, K562, K562R and KG-1). Among those synthesized derivatives, compounds 2a exhibited the best antiproliferative activity (IC50 = 0.276, 0.159, 0.312 and 0.271 µM to U937, K562, K562R and KG-1, respectively). In addition, 2a induced apoptosis in K562 and markedly arrested the cell cycle G2/M phase of K562. The Western blot assay showed that 2a is a potential inhibitor that can effectively suppress the expression of Bcl-2 and Mcl-1. The molecular docking study predicted that 2a had firm interactions with the active pockets of Bcl-2 and Mcl-1. Finally, in silico pharmacokinetic evaluation of 2a indicated its potential as an anti-leukemia drug lead in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hunan Key Laboratory of Traditional Chinese Veterinary Medicine, Hunan Agricultural University, Changsha 410128, China.
- Chinese Medicinal Materials Breeding Innovation Center of Yuelushan Laboratory, Changsha 410128, China.
Förderung
- National Key Research and Development Program of China
Zitieren
APA
Li, K., Ge, X., Liu, W., Huang, L., Lv, X., Tang, Y., He, Z., Yang, Y., Chen, M., Zeng, J., & Cheng, P. (2025). Synthesis and Biological Evaluation of Quercetagetin Derivatives as the Inhibitors of Mcl-1 and Bcl-2 Against Leukemia. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26062727
Vancouver
Li K, Ge X, Liu W, Huang L, Lv X, Tang Y, et al. Synthesis and Biological Evaluation of Quercetagetin Derivatives as the Inhibitors of Mcl-1 and Bcl-2 Against Leukemia. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26062727
BibTeX
@article{Li2025,
author = {Li, Kang and Ge, Xiaomei and Liu, Wei and Huang, Lei and Lv, Xinye and Tang, Yuhui and He, Zhehao and Yang, Yingxue and Chen, Miaofen and Zeng, Jianguo and Cheng, Pi},
title = {Synthesis and Biological Evaluation of Quercetagetin Derivatives as the Inhibitors of Mcl-1 and Bcl-2 Against Leukemia},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26062727}
}
EUVIMED